glp-1 crohn's disease with Disease: Safety, Risks and Clinical Guidance – Bolt Pharmacy GLP-1 and GLP-2 Orchestrate Intestine
Description
Healthcare professionals and patients are encouraged to report suspected adverse reactions via the Yellow Card Scheme (yellowcard.mhra.gov.uk), and the overall benefit-risk profile remains favourable for appropriate patients
Will research begin to shift toward identifying which patient subgroups benefit most from GLP-1s for weight loss, maximizing the value proposition
plantarum probiotic separately
Research into GLP-1 patches specifically is limited
